Georgia CTSA TL1/TL32 Visiting Scientist Program
"Advancing Lyme Disease Therapeutics Through A Multimodal Screening Approach" - Michael H. Ronzetti , University of Maryland, National Institutes of Health
Michael H. Ronzetti
Graduate Student
Early Translation Branch
Division of Preclinical Innovation
National Center for Advancing Translational Sciences
National Institutes of Health
REGISTER HERE for Zoom link
Lyme disease remains a significant public health concern with over half a million cases reported annually that results in an economic burden of nearly $3 billion. Current treatments fail to completely clear the infection in nearly 15% of cases and lose effectiveness as the disease progresses, highlighting the need for new and more potent therapeutics. By employing parallel approaches—phenotypic screening of live Borrelia burgdorferi sensu lato, the causative agent of Lyme disease, and target-based drug design focusing on a known protease—we have identified several promising candidates with potential applications for eradicating the bacteria in vivo.
